On Jul. 7, 2026, the World Health Organization (WHO) reported that the outbreak of the deadly Bundibugyo species of Ebola in the eastern Democratic Republic of the Congo (DRC) is expanding, while the push to accelerate testing and identify effective treatment options continues.

The outbreak’s “true scale has not yet been fully established,” said Dr. Anne Ancia, WHO’s representative to the DRC. “We would like to say it is stabilising, but frankly, we cannot say it yet”, she said. 

Speaking from Bunia, the capital of Ituri province at the heart of the outbreak, Dr. Ancia told reporters in Geneva that as of 4 July, the country’s Government has recorded 1,561 confirmed cases, including 506 deaths and 254 people recovered. More than 10,000 contacts are being monitored.

The current outbreak was declared on 15 May and has been unfolding in areas marked by active conflict, displacement and overstretched health services.

Encouraging developments include the progress made on testing, as daily capacity has increased from 30 tests in Kinshasa to more than 2,000, “thanks to 10 decentralised laboratories established in the affected provinces”, the WHO representative explained, with the most recent lab opening in Bunia.

Another positive step is the start of a clinical trial on 2 July to identify effective treatment options as there is no approved, proven cure for the Bundibugyo species of Ebola. The trial will evaluate two promising therapies, a monoclonal antibody, MBP134, and the antiviral remdesivir.

More than 1,200 treatment doses are available, and additional therapies can be incorporated into the trial as new evidence emerges.